In 2024, Ozempic, Wegovy, Mounjaro and Zepbound earned respectively $16.8bn ... which is a similar MoA to Eli Lilly's tirzepatide, widely regarded as the most effective GLP drug to have been ...

Zepbound is a weekly injectable prescription weight loss medication with the active ingredient tirzepatide. It’s a GLP-1 agonist drug that slows stomach emptying, meaning you feel fuller for ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

Eli Lilly's drive to provide as many treatment options as possible for its weight-loss drug Zepbound has continued with the launch of new high-dose vials sold at a $150 discount to its auto ...

Shares in Eli Lilly have weakened after CVS Health, one of the largest pharmacy benefit managers (PBMs) in the US, said it would no longer cover its obesity therapy Zepbound. The shares closed ...

Another drug called Zepbound contains the same active ingredient as Mounjaro and is FDA approved for weight loss. Some insurance providers may cover Zepbound for weight loss, although many don’t.